Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement

Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement

The anticoagulant edoxaban may be just as effective as warfarin for preventing heart attack or stroke in patients with atrial fibrillation (AF) who undergo transcatheter aortic valve replacement (TAVR), according to a large-scale international study led by Mount Sinai.

The ENVISAGE-TAVI AF trial is the largest to investigate an edoxaban-based strategy in this patient population compared with warfarin, which is currently the standard of care. It demonstrates that edoxaban is non-inferior to warfarin. The results, which could lead to an alternative treatment strategy, were announced Saturday, August 28, as a late-breaking clinical trial at the ESC Congress 2021 from the European Society of Cardiology and simultaneously published in The New England Journal of Medicine.

Referring a patient is easy. Just click the “Refer a Patient Online” button.

Learn More


Published

August 28, 2021

Created by

Physician's Channel - Mount Sinai New York

Featured Faculty

George Dangas, MD, PhD

George Dangas, MD, PhD

Professor, Medicine (Cardiology, and Surgery)
Icahn School of Medicine at Mount Sinai
Director of Cardiovascular Innovation, The Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai Health System

View full profile